Shield has announced that the US FDA has granted Shield an additional three years of Data Exclusivity for ACCRUFeR (ferric maltol). This is due to the clinical investigation conducted by Shield supporting the extension of the indication to include pediatric patients 10 years of age and older. This exclusivity will remain in place until 19 December 2028, in addition to the ACCRUFeR/FeRACCRU patent coverage valid until the mid-2030s. We note the strength of Shield’s recent operational updates and ....
